Context dependent neuroprotective properties of prion protein (PrP)

References

• Prusiner SB. Shattuck lecture—neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516 - 1526
   PubMed Web of Science ®Google Scholar
• Shastry BS. Neurodegenerative disorders of protein aggregation. Neurochem Int 2003; 43:1 - 7
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 2003; 302:814 - 818
   PubMed Web of Science ®Google Scholar
• Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 2008; 105:145 - 150
   PubMed Web of Science ®Google Scholar
• Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10:1055 - 1063
   PubMed Web of Science ®Google Scholar
• Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Mol Biotechnol 2006; 32:147 - 158
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004; 116:313 - 327
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363 - 13383
   PubMed Web of Science ®Google Scholar
• Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996; 15:1255 - 1264
   PubMed Web of Science ®Google Scholar
• Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302:871 - 874
   PubMed Web of Science ®Google Scholar
• Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308:1435 - 1439
   PubMed Web of Science ®Google Scholar
• Steele AD, Hutter G, Jackson WS, Heppner FL, Borkowski AW, King OD, et al. Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. Proc Natl Acad Sci USA 2008; 105:13626 - 13631
   PubMed Web of Science ®Google Scholar
• Felton LM, Cunningham C, Rankine EL, Waters S, Boche D, Perry VH. MCP-1 and murine prion disease: separation of early behavioural dysfunction from overt clinical disease. Neurobiol Dis 2005; 20:283 - 295
   PubMed Web of Science ®Google Scholar
• Steele AD. All quiet on the neuronal front: NMDA receptor inhibition by prion protein. J Cell Biol 2008; 181:407 - 409
   PubMed Web of Science ®Google Scholar
• Steele AD, Lindquist S, Aguzzi A. The prion protein knockout mouse: a phenotype under challenge. Prion 2007; 1:83 - 93
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 2007; 8:552 - 561
   PubMed Web of Science ®Google Scholar
• Steele AD, King OD, Jackson WS, Hetz CA, Borkowski AW, Thielen P, et al. Diminishing Apoptosis by Deletion of Bax or Overexpression of Bcl-2 Does Not Protect against Infectious Prion Toxicity In Vivo. J Neurosci 2007; 27:13022 - 13027
   PubMed Web of Science ®Google Scholar
• Watts JC, Westaway D. The prion protein family: diversity, rivalry and dysfunction. Biochim Biophys Acta 2007; 1772:654 - 672
   PubMed Web of Science ®Google Scholar
• Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008; 88:673 - 728
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci 2008; 31:439 - 477
   PubMed Web of Science ®Google Scholar
• Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 2007; 1772:629 - 644
   PubMed Web of Science ®Google Scholar
• McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 2004; 165:227 - 235
   PubMed Web of Science ®Google Scholar
• Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, et al. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 2005; 20:442 - 449
   PubMed Web of Science ®Google Scholar
• Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke 2006; 37:1296 - 1300
   Google Scholar
• Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol 2008; 181:551 - 565
   PubMed Web of Science ®Google Scholar
• Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH, et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 2007; 26:538 - 547
   PubMed Web of Science ®Google Scholar
• Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998; 93:203 - 214
   PubMed Web of Science ®Google Scholar
• Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125. EMBO J 2007; 26:548 - 558
   PubMed Web of Science ®Google Scholar
• Drisaldi B, Coomaraswamy J, Mastrangelo P, Strome B, Yang J, Watts JC, et al. Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B' region. J Biol Chem 2004; 279:55443 - 55454
   PubMed Web of Science ®Google Scholar
• Roucou X, Gains M, LeBlanc AC. Neuroprotective functions of prion protein. J Neurosci Res 2004; 75:153 - 161
   PubMed Web of Science ®Google Scholar
• Choi CJ, Anantharam V, Saetveit NJ, Houk RS, Kanthasamy A, Kanthasamy AG. Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death. Toxicol Sci 2007; 98:495 - 509
   PubMed Web of Science ®Google Scholar
• Anantharam V, Kanthasamy A, Choi CJ, Martin DP, Latchoumycandane C, Richt JA, et al. Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling. Free Radic Biol Med 2008; 45:1530 - 1541
   PubMed Web of Science ®Google Scholar
• Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002; 298:1781 - 1785
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007; 26:175 - 188
   PubMed Web of Science ®Google Scholar
• Chiesa R, Piccardo P, Biasini E, Ghetti B, Harris DA. Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci 2008; 28:13258 - 13267
   PubMed Web of Science ®Google Scholar
• Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang SL, et al. Degeneration of skeletal muscle, peripheral nerves and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 1994; 76:117 - 129
   PubMed Web of Science ®Google Scholar
• Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 2007; 104:11062 - 11067
   PubMed Web of Science ®Google Scholar
• Schwarze-Eicker K, Keyvani K, Gortz N, Westaway D, Sachser N, Paulus W. Prion protein (PrPc) promotes beta-amyloid plaque formation. Neurobiol Aging 2005; 26:1177 - 1182
   PubMed Web of Science ®Google Scholar
• Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128 - 1132
   PubMed Web of Science ®Google Scholar
• Lee KJ, Panzera A, Rogawski D, Greene LE, Eisenberg E. Cellular prion protein (PrPC) protects neuronal cells from the effect of huntingtin aggregation. J Cell Sci 2007; 120:2663 - 2671
   PubMed Web of Science ®Google Scholar
• Wang XF, Dong CF, Zhang J, Wan YZ, Li F, Huang YX, et al. Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro. Mol Cell Biochem 2008; 310:49 - 55
   PubMed Web of Science ®Google Scholar
• Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, et al. Gerstmann-Straussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology 1989; 39:1453 - 1461
   PubMed Web of Science ®Google Scholar
• Ishizawa K, Komori T, Shimazu T, Yamamoto T, Kitamoto T, Shimazu K, et al. Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Straussler-Scheinker syndrome P102L mutation complicated with dementia. Acta Neuropathol 2002; 104:342 - 350
   PubMed Web of Science ®Google Scholar
• Nicholl D, Windl O, de Silva R, Sawcer S, Dempster M, Ironside JW, et al. Inherited Creutzfeldt-Jakob disease in a British family associated with a novel 144 base pair insertion of the prion protein gene. J Neurol Neurosurg Psychiatry 1995; 58:65 - 69
   PubMed Web of Science ®Google Scholar
• Moore RC, Xiang F, Monaghan J, Han D, Zhang Z, Edstrom L, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001; 69:1385 - 1388
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Oyanagi K, Mori O, Kitamura S, Ohyama M, Terashi A, et al. Variant Gerstmann-Straussler syndrome with the P105L prion gene mutation: an unusual case with nigral degeneration and widespread neurofibrillary tangles. Acta Neuropathol 1999; 98:506 - 511
   PubMed Web of Science ®Google Scholar
• Nitrini R, Teixeira da Silva LS, Rosemberg S, Caramelli P, Carrilho PE, Iughetti P, et al. Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17. Arq Neuropsiquiatr 2001; 59:161 - 164
   PubMed Web of Science ®Google Scholar
• Collinge J, Brown J, Hardy J, Mullan M, Rossor MN, Baker H, et al. Inherited prion disease with 144 base pair gene insertion 2. Clinical and pathological features. Brain 1992; 115:687 - 710
   PubMed Web of Science ®Google Scholar
• Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994; 8:121 - 127
   PubMed Web of Science ®Google Scholar
• Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25:402 - 405
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287:1265 - 1269
   PubMed Web of Science ®Google Scholar
• Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87:493 - 506
   PubMed Web of Science ®Google Scholar
• Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA 2006; 103:3416 - 3421
   PubMed Web of Science ®Google Scholar
• Arboleda-Velasquez JF, Zhou Z, Shin HK, Louvi A, Kim HH, Savitz SI, et al. Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci USA 2008; 105:4856 - 4861
   PubMed Web of Science ®Google Scholar
• Steele AD, Jackson WS, King OD, Lindquist S. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci USA 2007; 104:1983 - 1988
   PubMed Web of Science ®Google Scholar
• Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1957; 46:208 - 209
   PubMed Web of Science ®Google Scholar
• Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004; 24:9434 - 9440
   PubMed Web of Science ®Google Scholar
• Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 2005; 20:1 - 11
   PubMed Web of Science ®Google Scholar
• Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999; 8:397 - 407
   PubMedGoogle Scholar
• Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002; 99:8968 - 8973
   PubMed Web of Science ®Google Scholar
• Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006; 311:1471 - 1474
   PubMed Web of Science ®Google Scholar